2024
A phase II trial of UGT1A1 genotype-guided FOLFIRI plus bevacizumab as first-line therapy for advanced, unresectable colorectal cancer
Sanoff H, Deal A, Patel J, Sorah J, Gaddy J, O’Neil B, Turk A, Irvin W, Boles J, Lee M, McRee A, Wardell A, Weck K, Basch E, Wood W, Innocenti F. A phase II trial of UGT1A1 genotype-guided FOLFIRI plus bevacizumab as first-line therapy for advanced, unresectable colorectal cancer. The Oncologist 2024, oyae122. PMID: 38837045, DOI: 10.1093/oncolo/oyae122.Peer-Reviewed Original ResearchProgression-free survivalMetastatic colorectal cancerOverall survivalIrinotecan doseColorectal cancerMedian progression-free survivalMetastatic colorectal cancer patientsEstimates of overall survivalFirst-line settingUnresectable colorectal cancerRates of neutropeniaFirst-line therapyPhase II trialPatient-reported adverse eventsRate of diarrheaG3/4 toxicitiesUGT1A1 genotypeIrinotecan metabolismFirst-linePrimary endpointSecondary endpointsAdverse eventsFOLFIRIHistorical controlsNon-genotypeGenetic ancestry-associated differences in genomic profiling and treatment patterns in pancreatic ductal adenocarcinoma (PDAC).
Gaddy J, Li G, Keller-Evans R, Bray D, MILLS J, Oberstein P, Kunz P, Sivakumar S. Genetic ancestry-associated differences in genomic profiling and treatment patterns in pancreatic ductal adenocarcinoma (PDAC). Journal Of Clinical Oncology 2024, 42: 4138-4138. DOI: 10.1200/jco.2024.42.16_suppl.4138.Peer-Reviewed Original ResearchPancreatic ductal adenocarcinomaClinico-genomic databaseGenetic ancestryAFRS patientsSocioeconomic statusPattern of gene alterationsPotential impact of genomicsSNP-based approachTreatment patternsGenomic profilingPopulation-level risk factorsImpact of genomicsCancer treatment courseClinical care patternsLow socioeconomic statusComprehensive genomic profilingOverall US populationNon-genomic factorsYounger median ageRate of surgeryImpact patient outcomesGenomic differencesAncestry distributionGenomic landscapeAncestry groups
2023
Abstract C129: Impact of COVID-19 on colorectal cancer screening disparities: Results from a large commercially insured population in the United States
Siddique A, Wang R, Gaddy J, Gross C, Ma X. Abstract C129: Impact of COVID-19 on colorectal cancer screening disparities: Results from a large commercially insured population in the United States. Cancer Epidemiology Biomarkers & Prevention 2023, 32: c129-c129. DOI: 10.1158/1538-7755.disp23-c129.Peer-Reviewed Original ResearchBlue Cross Blue ShieldColorectal cancer screeningColorectal cancer screening disparitiesLow socioeconomic statusCancer screening disparitiesScreening ratesHigher socioeconomic statusSocioeconomic statusScreening disparitiesCommercially insured populationColorectal cancerColorectal cancer screening ratesImpact of COVID-19Burden of colorectal cancerColorectal cancer incidenceCancer health disparitiesCRC-related mortalityNeighborhood socioeconomic statusSocioeconomic status quintileSocial deprivation indexSocioeconomic status areasNon-Hispanic blacksNon-urgent careSocially deprived areasEthnic minoritized populationsRace, geography, and risk of breast cancer treatment delays: A population‐based study 2004–2015
Reeder‐Hayes K, Jackson B, Baggett C, Kuo T, Gaddy J, LeBlanc M, Bell E, Green L, Wheeler S. Race, geography, and risk of breast cancer treatment delays: A population‐based study 2004–2015. Cancer 2023, 129: 925-933. PMID: 36683417, DOI: 10.1002/cncr.34573.Peer-Reviewed Original ResearchConceptsBreast cancer treatment delaysTreatment delayMagnitude of racial disparitiesNon-Black patientsStage I-III breast cancerI-III breast cancerPoor-quality carePopulation health resourcesRisk of treatment delayBlack patientsBreast cancer survivalCancer treatment delayPopulation-based studyDiagnosis to first treatmentAssociated with riskBreast cancerCancer RegistryObservational cohort of patientsTreatment delay >Health resourcesPopulation-basedPoisson regressionCancer survivalSociodemographic dataRacial disparitiesObesity, Cancer, and Health Equity
Nyrop K, Gaddy J, Charlot M. Obesity, Cancer, and Health Equity. American Journal Of Preventive Medicine 2023, 64: 595-598. PMID: 36610923, DOI: 10.1016/j.amepre.2022.10.024.Peer-Reviewed Original ResearchSeeking Racial Equity in Hematology and Oncology: a Fellow-Led Educational Series to Promote Reflection and Action
Stein J, Gaddy J, Sorah J, Wooten M, Gibson K, Collichio F. Seeking Racial Equity in Hematology and Oncology: a Fellow-Led Educational Series to Promote Reflection and Action. Journal Of Cancer Education 2023, 38: 1241-1244. PMID: 36598746, PMCID: PMC10463164, DOI: 10.1007/s13187-022-02255-8.Peer-Reviewed Original ResearchConceptsGraduate medical education programsHealth system levelMedical education programsEffects of implicit biasImproved comfort levelRacial inequalitySystemic racismAwareness of racial inequalityMedical residentsImprove awarenessRacial equityImprove knowledgeGroup discussionsEducation programsUniversity of North CarolinaLikert scaleEducation seriesImplicit biasComfort levelLay mediaEducational gapLived experiencePerceptions of racial inequalityParticipantsEducation curriculum
2022
Addressing Racial, Ethnic, and Age Disparities in Cancer Clinical Trial Enrollment
Gaddy JJ, Gross CP. Addressing Racial, Ethnic, and Age Disparities in Cancer Clinical Trial Enrollment. JAMA Oncology 2022, 8: 1792-1793. PMID: 36301581, DOI: 10.1001/jamaoncol.2022.5006.Peer-Reviewed Original ResearchEvaluation of facilitators and barriers of timely breast cancer care in North Carolina (NC): A qualitative study.
Gaddy J, Teal R, Bell E, Wheeler S, Reeder-Hayes K. Evaluation of facilitators and barriers of timely breast cancer care in North Carolina (NC): A qualitative study. Journal Of Clinical Oncology 2022, 40: 134-134. DOI: 10.1200/jco.2022.40.28_suppl.134.Peer-Reviewed Original ResearchCancer care deliverySocial determinants of healthArea Health Education CenterDeterminants of healthBreast cancer careSocial determinantsCare deliveryCancer careBlack patientsHealthcare systemQuality of cancer careQualitative studyIdentification of emergent themesInitiation of breast cancer treatmentOverall quality of cancer careAdverse social determinantsPatients' social determinantsProvision of social support servicesBreast cancer cliniciansHealth Education CenterSupportive healthcare providersSocial support servicesNorth CarolinaTreatment delayNon-black womenSeeking racial equity in hematology and oncology: A fellow-led educational series to promote reflection and action.
Stein J, Gaddy J, Sorah J, Wooten M, Gibson K, Collichio F. Seeking racial equity in hematology and oncology: A fellow-led educational series to promote reflection and action. Journal Of Clinical Oncology 2022, 40: 11004-11004. DOI: 10.1200/jco.2022.40.16_suppl.11004.Peer-Reviewed Original ResearchUniversity of North CarolinaImplicit biasSystemic racismAwareness of implicit biasAcademic medical centerPatients of colorRacial inequalityHealth disparitiesImprove careImprove racial equityEducation curriculumAwareness of racial inequalityOncology fellowsJournal clubRacial equityImprove knowledgeGroup discussionsLikert scaleMedical CenterEducation seriesComfort levelLay mediaLived experiencePerceptions of racial inequalityParticipantsIntegrated approach to collecting patient reported toxicities in a colorectal cancer trial.
Gaddy J, Sanoff H, Deal A, Basch E, Wood W. Integrated approach to collecting patient reported toxicities in a colorectal cancer trial. Journal Of Clinical Oncology 2022, 40: 51-51. DOI: 10.1200/jco.2022.40.4_suppl.051.Peer-Reviewed Original ResearchDose decreaseSevere symptomsToxicity ratesSevere toxicityClinical trialsGenotype-guided dosing strategyAppropriate dose modificationPRO-CTCAEStandard drug dosesAdverse event assessmentMulti-center clinical trialClinically relevant issuesColorectal cancer trialsHematologic toxicityMCRC patientsDose modificationAbdominal painAdvanced CRCToxicity gradeCycling patientsClinical characteristicsDosing strategiesAdverse eventsDrug doseClinician grading
2021
Racial differences in impact of geography on breast cancer treatment delay.
Reeder-Hayes K, Baggett C, Jackson B, Kuo T, Gaddy J, Bell E, Green L, Wheeler S. Racial differences in impact of geography on breast cancer treatment delay. Journal Of Clinical Oncology 2021, 39: 81-81. DOI: 10.1200/jco.2020.39.28_suppl.81.Peer-Reviewed Original ResearchArea Health Education CenterBlack patientsRacial disparitiesBreast cancer treatment delaysLocal health system characteristicsBlack breast cancer patientsLikelihood of treatment delaysBlack womenTreatment delayNon-Black patientsStage I-III breast cancerRisk ratioHealth system factorsPoor quality careCancer registry dataI-III breast cancerPopulation health resourcesHealth Education CenterPatients receive careBlack patients receive careRisk of treatment delayPatient-level factorsModified Poisson regressionCancer treatment delaySignificant racial disparitiesThe Ethical Imperative of Equity in Oncology: Lessons Learned From 2020 and a Path Forward.
Marron J, Charlot M, Gaddy J, Rosenberg A. The Ethical Imperative of Equity in Oncology: Lessons Learned From 2020 and a Path Forward. American Society Of Clinical Oncology Educational Book 2021, 41: e13-e19. PMID: 34061560, DOI: 10.1200/edbk_100029.Peer-Reviewed Original ResearchConceptsU.S. health careOncology communityProfessional medical organizationsCancer careRacial/ethnic disparitiesOncology workforceHealth careStructural racismMedical organizationsOncologyClinical practiceEthical principlesEthical responsibilityPracticing oncologistsEthical imperativesCareCOVID-19 pandemicOptimize equityUnited StatesCOVID-19CommunityDisparitiesWork—andInequalityWorkforce
2016
Racial/Ethnic Disparity in Treatment for Prostate Cancer: Does Cancer Severity Matter?
Moses K, Orom H, Brasel A, Gaddy J, Underwood W. Racial/Ethnic Disparity in Treatment for Prostate Cancer: Does Cancer Severity Matter? Urology 2016, 99: 76-83. PMID: 27667157, PMCID: PMC5191943, DOI: 10.1016/j.urology.2016.07.045.Peer-Reviewed Original ResearchConceptsProstate cancerOdds of receiving treatmentReceipt of treatmentDefinitive treatmentHispanic menWhite menD'Amico risk classificationDisease severityContext of disease severityOdds of treatmentLogistic regression analysisApproach to treatmentIntermediate-riskDecreased oddsHigh riskAA menAsian menRisk categoriesRisk classificationCancerProstateTreatmentRegression analysisMenTreatment variationRacial/ethnic differences in the relative risk of receipt of specific treatment among men with prostate cancer
Moses K, Orom H, Brasel A, Gaddy J, Underwood W. Racial/ethnic differences in the relative risk of receipt of specific treatment among men with prostate cancer. Urologic Oncology Seminars And Original Investigations 2016, 34: 415.e7-415.e12. PMID: 27161898, PMCID: PMC4996674, DOI: 10.1016/j.urolonc.2016.04.002.Peer-Reviewed Original ResearchConceptsReceipt of radical prostatectomyRadiation therapyProstate cancerRelative risk ratiosCombination therapyDefinitive treatmentExternal beam radiation therapyBeam radiation therapyWhite menEnd Results ProgramHispanic menLogistic regression analysisPredictors of receiptRadical prostatectomyImprove physician educationSignificant public health issueEnd ResultsBrachytherapySpecific treatmentRisk ratioProstateAA menAfrican AmericansRelative riskCryotherapy
2015
MP5-15 EMERGING DISPARITY IN TREATMENT FOR PROSTATE CANCER AMONG HISPANIC MEN- DATA FROM SEER 2004–2009
Moses K, Orom H, Brasel A, Gaddy J, Underwood W. MP5-15 EMERGING DISPARITY IN TREATMENT FOR PROSTATE CANCER AMONG HISPANIC MEN- DATA FROM SEER 2004–2009. Journal Of Urology 2015, 193: e50-e51. DOI: 10.1016/j.juro.2015.02.242.Peer-Reviewed Original Research
2009
Mapatumumab, A TRAIL Receptor 1 Agonist Antibody, Induces Apoptosis in Bortezomib Resistant Multiple Myeloma.
Ghoshal P, Chitta K, Vujcic S, Gaddy J, Miles K, Stein L, Sher T, Lee K, Chanan-Khan A. Mapatumumab, A TRAIL Receptor 1 Agonist Antibody, Induces Apoptosis in Bortezomib Resistant Multiple Myeloma. Blood 2009, 114: 2832. DOI: 10.1182/blood.v114.22.2832.2832.Peer-Reviewed Original ResearchTumor necrosis factor-related apoptosis-inducing ligandEntity's Board of DirectorsMultiple myelomaResistant MMTherapeutic optionsCombination treatment of MM cellsBortezomib-resistant multiple myelomaWild typeFactor-related apoptosis-inducing ligandBortezomib-resistant diseaseResistant multiple myelomaTreatment of MM cellsResistance to bortezomibInhibition of tumor cell viabilityApoptosis-inducing ligandCell linesExpression of Bcl-2Limited therapeutic optionsMM cell linesConventional therapeutic agentsTumor cell viabilityBR cellsEnhanced cell killingAnnexin V stainingActivation of caspase-8